1. Home
  2. VYGR vs MASS Comparison

VYGR vs MASS Comparison

Compare VYGR & MASS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VYGR
  • MASS
  • Stock Information
  • Founded
  • VYGR 2013
  • MASS 2012
  • Country
  • VYGR United States
  • MASS United States
  • Employees
  • VYGR N/A
  • MASS N/A
  • Industry
  • VYGR Biotechnology: Pharmaceutical Preparations
  • MASS Medical/Dental Instruments
  • Sector
  • VYGR Health Care
  • MASS Health Care
  • Exchange
  • VYGR Nasdaq
  • MASS Nasdaq
  • Market Cap
  • VYGR 206.9M
  • MASS 235.8M
  • IPO Year
  • VYGR 2015
  • MASS 2020
  • Fundamental
  • Price
  • VYGR $3.36
  • MASS $6.25
  • Analyst Decision
  • VYGR Strong Buy
  • MASS Strong Buy
  • Analyst Count
  • VYGR 7
  • MASS 3
  • Target Price
  • VYGR $14.50
  • MASS $8.00
  • AVG Volume (30 Days)
  • VYGR 725.5K
  • MASS 267.0K
  • Earning Date
  • VYGR 08-06-2025
  • MASS 08-05-2025
  • Dividend Yield
  • VYGR N/A
  • MASS N/A
  • EPS Growth
  • VYGR N/A
  • MASS N/A
  • EPS
  • VYGR N/A
  • MASS N/A
  • Revenue
  • VYGR $42,580,000.00
  • MASS $65,560,000.00
  • Revenue This Year
  • VYGR N/A
  • MASS N/A
  • Revenue Next Year
  • VYGR $107.07
  • MASS $21.68
  • P/E Ratio
  • VYGR N/A
  • MASS N/A
  • Revenue Growth
  • VYGR N/A
  • MASS 37.93
  • 52 Week Low
  • VYGR $2.65
  • MASS $1.81
  • 52 Week High
  • VYGR $8.28
  • MASS $8.06
  • Technical
  • Relative Strength Index (RSI)
  • VYGR 49.16
  • MASS 44.90
  • Support Level
  • VYGR $3.30
  • MASS $5.85
  • Resistance Level
  • VYGR $3.49
  • MASS $6.42
  • Average True Range (ATR)
  • VYGR 0.21
  • MASS 0.35
  • MACD
  • VYGR -0.02
  • MASS -0.01
  • Stochastic Oscillator
  • VYGR 33.33
  • MASS 25.06

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

About MASS 908 Devices Inc.

908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific.

Share on Social Networks: